Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03, Zacks reports. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.

Repligen Stock Performance

Repligen stock traded up $12.46 during mid-day trading on Thursday, reaching $163.19. 425,022 shares of the stock traded hands, compared to its average volume of 560,983. The stock has a market capitalization of $9.14 billion, a PE ratio of -441.03, a price-to-earnings-growth ratio of 4.08 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The business’s 50-day moving average is $155.04 and its 200-day moving average is $148.71.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several analyst reports. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. HC Wainwright dropped their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.